Everything about Tyrosinase-IN-12
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial goals were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis peopl